These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26866663)

  • 1. Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.
    Bainschab A; Quehenberger F; Greinix HT; Krause R; Wölfler A; Sill H; Zebisch A
    Leuk Res; 2016 Mar; 42():47-51. PubMed ID: 26866663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.
    Ali AM; Weisel D; Gao F; Uy GL; Cashen AF; Jacoby MA; Wartman LD; Ghobadi A; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Schroeder MA; Westervelt P; DiPersio JF; Welch JS
    Cancer Med; 2017 Dec; 6(12):2814-2821. PubMed ID: 29058375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
    Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment.
    Lorenzana N; Avila LF; Alonso S; Colado E; Bernal T
    Ann Hematol; 2017 Nov; 96(11):1833-1840. PubMed ID: 28803258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
    Bradley AM; Deal AM; Buie LW; van Deventer H
    Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
    Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
    Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
    Radujkovic A; Dietrich S; Bochtler T; Krämer A; Schöning T; Ho AD; Dreger P; Luft T
    Eur J Haematol; 2014 Aug; 93(2):112-7. PubMed ID: 24628527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.
    Ofran Y; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Merkel D
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e95-9. PubMed ID: 25819366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
    Merkel D; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Ofran Y
    Am J Hematol; 2013 Feb; 88(2):130-4. PubMed ID: 23345248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
    Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
    Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine. Acute myeloid leukaemia: no progress.
    Prescrire Int; 2014 Apr; 23(148):92-4. PubMed ID: 24860891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia.
    Mayer K; Hahn-Ast C; Mückter S; Schmitz A; Krause S; Felder L; Bekeredjian-Ding I; Molitor E; Brossart P; von Lilienfeld-Toal M
    Support Care Cancer; 2015 May; 23(5):1321-9. PubMed ID: 25617073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
    Griffin PT; Komrokji RS; De Castro CM; Rizzieri DA; Melchert M; List AF; Lancet JE
    Am J Hematol; 2015 Sep; 90(9):796-9. PubMed ID: 26089240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
    Falantes JF; Calderón C; Márquez-Malaver FJ; Aguilar-Guisado M; Martín-Peña A; Martino ML; Montero I; González J; Parody R; Pérez-Simón JA; Espigado I
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):80-6. PubMed ID: 24220615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome.
    Lee JH; Lee KH; Lee JH; Kim DY; Kim SH; Lim SN; Kim SD; Choi Y; Lee SM; Lee WS; Choi MY; Joo YD
    Leuk Res; 2011 Apr; 35(4):499-503. PubMed ID: 20674021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.
    Pohlen M; Marx J; Mellmann A; Becker K; Mesters RM; Mikesch JH; Schliemann C; Lenz G; Müller-Tidow C; Büchner T; Krug U; Stelljes M; Karch H; Peters G; Gerth HU; Görlich D; Berdel WE
    Haematologica; 2016 Oct; 101(10):1208-1215. PubMed ID: 27470601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection Rate and Risk Factors in Patients Treated With Azacitidine.
    Orero M; Villegas C; Ortiz S; Javier KP; Costa S; Pérez PL; Roig M; Linares M
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):e141-2. PubMed ID: 26257105
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibiotic use during cytarabine consolidation in acute myeloid leukemia.
    Vale CA; Egan PC; Ingham R; Farmakiotis D; Reagan JL
    Ann Hematol; 2021 Jan; 100(1):79-84. PubMed ID: 32870366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.